Search clinical trials for: Oblimerson sodium, G3139

Total 10438 results

Genta Incorporated

Terminated

Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

Advanced Melanoma and Normal or Impaired | Hepatic Function
National Cancer Institute (NCI)

Completed

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Waldenström Macroglobulinemia

United States
Genta Incorporated

Completed

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | CLL

United States
Genta Incorporated

Completed

A Phase I Study of G3139 Subcutaneous in Solid Tumors

Tumors

United States
Genta Incorporated

Withdrawn

This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

Lymphocytic Leukemia
Genta Incorporated

Completed

Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

Normal Renal Function | Mildly Impaired Renal Function | Moderately Impaired Renal Function

United States
National Cancer Institute (NCI)

Completed

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage IV Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin | Stage I Neuroendocrine Carcinoma of the Skin

United States
Genta Incorporated

Completed

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Solid Tumors

United States
National Cancer Institute (NCI)

Terminated

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

Gastrointestinal Stromal Tumor

United States
National Cancer Institute (NCI)

Completed

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Terminated

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Stage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma... and other conditions

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer

United States
Genta Incorporated

Completed

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma (AGENDA)

Melanoma

United States, France, United Kingdom, Spain, Switzerland, Australia, Canada, Germany, Poland, Italy, Austria, Czech Republic
Genta Incorporated

Completed

A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

Advanced Melanoma
Genta Incorporated

Completed

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Completed

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia and other conditions

United States
National Cancer Institute (NCI)

Completed

Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer

Lung Cancer

United States
Genta Incorporated

Completed

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center

Completed

Chemotherapy in Treating Patients With Solid Tumors

Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer

United States
M.D. Anderson Cancer Center
Genta Incorporated

Terminated

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Melanoma

United States
Genta Incorporated
National Cancer Institute (NCI)

Unknown

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

Lung Cancer

United States, Canada, Russian Federation
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

Melanoma (Skin)

United States
European Organisation for Research and Treatment...

Completed

Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate

Prostate Cancer

Belgium, Poland, Italy, Austria, France, Denmark, Netherlands, United Kingdom, Israel, Spain, Portugal
National Cancer Institute (NCI)

Terminated

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Cardiac Toxicity

United States
The University of Texas Health Science Center at...
National Cancer Institute (NCI)

Completed

Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Colorectal Cancer

United States
Genta Incorporated

Unknown

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Melanoma

United States
Genta Incorporated

Completed

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Liver Cancer

Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules

Advanced Solid Tumors

China
National Cancer Institute (NCI)

Completed

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

Advanced Cancer

China
National Cancer Institute (NCI)

Completed

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Terminated

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

United States
Genta Incorporated

Completed

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
Genta Incorporated

Completed

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
University of Delaware

Completed

Adverse Neurogenic Actions of Dietary Salt

Blood Pressure

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

ALK-positive NSCLC

China
University of Nebraska
National Cancer Institute (NCI); Genta Incorporated

Terminated

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
Aga Khan University
Zeenat Qureshi Stroke Institute

Recruiting

Best Solution Identification to Prevent Hyperchloremia Combinations of Sodium Chloride and Sodium Acetate IV Fluids Along With Standard of Care Treatment in Acute Stroke Patients (sodium acetate)

Stroke, Acute

Pakistan
The University of Texas Health Science Center at...
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
British Columbia Cancer Agency
National Cancer Institute (NCI)

Completed

Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Lymphoma

Canada, United States

Search clinical trials for: Oblimerson sodium, G3139

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations